[Edaily] C&R Research led EMA approval of ‘EYELEA’ Phase 3 IND clinical trial
C&R Research successfully carried out EMA approval for the Phase 3 IND clinical trial of ‘EYELEA’ Biosimilar with Rophibio, Inc.
We provided additional news on the conduct of global clinical trials following IND approval by the Food and Drug Administration (FDA) earlier this year. This clinical trial will be conducted simultaneously in several countries in Europe.
